Bromodomain and extra-terminal (BET) family member proteins (BRD2, BRD3, BRD4 and
BRDT) play a pivotal role in interpreting the epigenetic information of histone Kac …

Prostate cancer is a major health issue in western countries and is the second leading
cause of cancer death in American men. Prostate cancer depends on the androgen receptor …

Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …

The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

Androgen deprivation therapies (ADTs) are important treatments which inhibit androgen-
induced prostate cancer (PCa) progression by either preventing androgen biosynthesis (eg …

Rhabdomyosarcoma (RMS) is a highly metastatic soft-tissue sarcoma that often develops
resistance to current therapies, including vincristine. Since the existing treatments have not …

Prostate cancer (PCa) is the second most common malignancy among men worldwide.
Although early-stage disease is curable, advanced stage PCa is mostly incurable and …

Abstract Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes
stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies …

Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate
cancer frequently seen after prolonged treatment of castration resistant prostate cancer …